Form 13-F position report

LYRA THERAPEUTICS INC

Reported by MORGAN STANLEY

LYRA CUSIP 55234L105 Manager CIK 0000895421

Reported 811,745 shares, up 747,353 (1160.6%) from the prior quarter.

Reported value -43.9%; share count 1160.6% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q2 2024
Shares 811,745 Quarter-end amount reported
Reported value $224,610 Fair value at quarter end
Consecutive quarters held 2 Through Q2 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 41000
2022-03-31 33000
2022-06-30 0
2022-12-31 3
2023-03-31 0
2023-06-30 2096
2023-09-30 0
2024-03-31 400519
2024-06-30 224610
2024-09-30 167663
2024-12-31 44682
2025-03-31 8287
2025-06-30 0
2025-06-30 19389
2025-09-30 8335
2025-12-31 1029
2026-03-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

17 quarters
Quarterly reported position history for LYRA THERAPEUTICS INC held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q1 2026 Reduced 0 -334 (-100.0%) 0 $0 2026-05-15
Q4 2025 Reduced 334 -943 (-73.8%) < 0.01% $1,029 2026-02-13
Q3 2025 Reduced 1,277 -887 (-41.0%) < 0.01% $8,335 2025-11-14
Q2 2025 New 2,164 +2,164 (0.0%) < 0.01% $19,389 2025-08-15
Q2 2025 Reduced 0 -65,619 (-100.0%) 0 $0 2025-08-15
Q1 2025 Reduced 65,619 -150,866 (-69.7%) < 0.01% $8,287 2025-05-15
Q4 2024 Reduced 216,485 -435,896 (-66.8%) < 0.01% $44,682 2025-02-14
Q3 2024 Reduced 652,381 -159,364 (-19.6%) < 0.01% $167,663 2024-11-14
Q2 2024 Added 811,745 +747,353 (1160.6%) < 0.01% $224,610 2024-08-14
Q1 2024 New 64,392 +64,392 (0.0%) < 0.01% $400,519 2024-05-15
Q3 2023 Reduced 0 -510 (-100.0%) 0 $0 2023-11-15
Q2 2023 New 510 +510 (0.0%) < 0.01% $2,096 2023-08-14
Q1 2023 Reduced 0 -1 (-100.0%) 0 $0 2023-05-15
Q4 2022 New 1 +1 (0.0%) < 0.01% $3 2023-02-14
Q2 2022 Reduced 0 -8,085 (-100.0%) 0 $0 2022-08-15
Q1 2022 Reduced 8,085 -1,346 (-14.3%) < 0.01% $33,000 2022-05-13
Q4 2021 Reduced 9,431 -20,732 (-68.7%) < 0.01% $41,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

94 managers reported LYRA THERAPEUTICS INC for Q2 2024.

Managers reporting LYRA THERAPEUTICS INC in Q2 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
PERCEPTIVE ADVISORS LLC Unchanged 12,757,562 0 0.09% $3,533,844 17 qtrs
CITADEL ADVISORS LLC Added 4,772,816 +433,715 < 0.01% $1,320,638 8 qtrs
BlackRock Inc Added 2,829,978 +2,678,059 < 0.01% $783,055 17 qtrs
Samsara BioCapital LLC Unchanged 2,780,261 0 0.16% $769,298 9 qtrs
VANGUARD GROUP INC Added 1,730,915 +249,434 < 0.01% $478,944 17 qtrs
Ikarian Capital LLC Unchanged 1,056,829 0 0.05% $292,424 16 qtrs
Rosalind Advisors Inc Reduced 1,034,773 -109,751 0.22% $286,321 3 qtrs
ACADIAN ASSET MANAGEMENT LLC New 985,631 +985,631 < 0.01% $271,000 1 qtr
MORGAN STANLEY This report Added 811,745 +747,353 < 0.01% $224,610 2 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 755,095 +395,664 < 0.01% $208,966 17 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2024
Filed
August 14, 2024
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
811,745
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.